Monsanto India

Fair trade regulator CCI in 2016 ordered the unit to carry out the probe after the agriculture ministry and some local seed companies complained that Monsanto was charging unreasonably high royalty fees for its GM technology.

The Supreme Court ruled on Tuesday that Monsanto can claim patents on its genetically modified (GM) cotton seeds, a victory for the US company that is expected to encourage biotechnology firms to step up investment in India.

"Today's order will have wide-ranging, negative implications for biotech-based innovation across many sectors within India," said Monsanto India.

As a number of international establishments have been exploring investment opportunities in Uttar Pradesh, Chief Minister Yogi Adityanath will tomorrow meet representatives of major American companies including Facebook, Adobe, Coca Cola, Mastercard, Monsanto, Uber, Honeywell, P&G, Oracle and GE Health and Cargill, in Lucknow.

One of India's biggest cotton-growing states has formed a panel to investigate how 15 percent of the state's cotton acreage has been planted with a non-approved genetically modified strain developed by Monsanto and may bring criminal charges.

India could prevent foreign firms monopolising the market for genetically modified seeds by allowing the sale of only locally developed varieties, the think tank said.

The US company's joint venture Mahyco Monsanto Biotech (MMB) took Hyderabad-based Nuziveedu Seeds Ltd to court in 2015, claiming patent infringements and accusing the Indian company of continuing to use Monsanto's technology after MMB had cancelled its licensing contract.

The Bayer-Monsanto deal, announced in September 2016, would create create the world's biggest seed and pesticide firm.

Under the open offer, Bayer will acquire up to 44.88 lakh shares of Monsanto India from public shareholders at a price of Rs 2,481.60, which is nearly 4 per cent higher from Tuesday's closing price of Rs 2,392.1 on the National Stock Exchange.

Among individual stocks, Monsanto India shares will in focus today as Bayer Group announced a mandatory offer to buy back up to 26 per cent additional stake in Monsanto India for over Rs 1,100 crore.

German pharma and chemical major Bayer group announced mandatory open offer to buy up to 26 per cent additional stake in the Monsanto India Ltd for over Rs 1,100 crore following its global deal to acquire US-based biotech major.

Bayer Cropscience is the Indian subsidiary of German-based Bayer AG and is engaged in the manufacturing of insecticides, fungicides and herbicides.

Monsanto Co has withdrawn an application seeking approval for its next generation of genetically modified cotton seeds in India, a major escalation in a long-running dispute between New Delhi and the world's biggest seed maker.

The Indian government is actively promoting the new homegrown seeds, having already capped prices and royalties that the world's largest seed company is able to charge.

US-biotech major Monsanto on Friday said its board would review the revised nearly $65-billion takeover bid from German pharma and chemical giant Bayer AG.

Fair trade regulator CCI in 2016 ordered the unit to carry out the probe after the agriculture ministry and some local seed companies complained that Monsanto was charging unreasonably high royalty fees for its GM technology.

The Supreme Court ruled on Tuesday that Monsanto can claim patents on its genetically modified (GM) cotton seeds, a victory for the US company that is expected to encourage biotechnology firms to step up investment in India.

"Today's order will have wide-ranging, negative implications for biotech-based innovation across many sectors within India," said Monsanto India.

As a number of international establishments have been exploring investment opportunities in Uttar Pradesh, Chief Minister Yogi Adityanath will tomorrow meet representatives of major American companies including Facebook, Adobe, Coca Cola, Mastercard, Monsanto, Uber, Honeywell, P&G, Oracle and GE Health and Cargill, in Lucknow.

One of India's biggest cotton-growing states has formed a panel to investigate how 15 percent of the state's cotton acreage has been planted with a non-approved genetically modified strain developed by Monsanto and may bring criminal charges.

India could prevent foreign firms monopolising the market for genetically modified seeds by allowing the sale of only locally developed varieties, the think tank said.

The US company's joint venture Mahyco Monsanto Biotech (MMB) took Hyderabad-based Nuziveedu Seeds Ltd to court in 2015, claiming patent infringements and accusing the Indian company of continuing to use Monsanto's technology after MMB had cancelled its licensing contract.

The Bayer-Monsanto deal, announced in September 2016, would create create the world's biggest seed and pesticide firm.

Under the open offer, Bayer will acquire up to 44.88 lakh shares of Monsanto India from public shareholders at a price of Rs 2,481.60, which is nearly 4 per cent higher from Tuesday's closing price of Rs 2,392.1 on the National Stock Exchange.

Among individual stocks, Monsanto India shares will in focus today as Bayer Group announced a mandatory offer to buy back up to 26 per cent additional stake in Monsanto India for over Rs 1,100 crore.

German pharma and chemical major Bayer group announced mandatory open offer to buy up to 26 per cent additional stake in the Monsanto India Ltd for over Rs 1,100 crore following its global deal to acquire US-based biotech major.

Bayer Cropscience is the Indian subsidiary of German-based Bayer AG and is engaged in the manufacturing of insecticides, fungicides and herbicides.

Monsanto Co has withdrawn an application seeking approval for its next generation of genetically modified cotton seeds in India, a major escalation in a long-running dispute between New Delhi and the world's biggest seed maker.

The Indian government is actively promoting the new homegrown seeds, having already capped prices and royalties that the world's largest seed company is able to charge.

US-biotech major Monsanto on Friday said its board would review the revised nearly $65-billion takeover bid from German pharma and chemical giant Bayer AG.